You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmisulpride
Accession NumberDB06288
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAmisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.
Structure
Thumb
Synonyms
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide
Aminosultopride
Amisulprida
Amisulpridum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DenibanSanofi-Aventis
SolianSanofi-Aventis
Brand mixturesNot Available
SaltsNot Available
Categories
UNII8110R61I4U
CAS number71675-85-9
WeightAverage: 369.479
Monoisotopic: 369.172227057
Chemical FormulaC17H27N3O4S
InChI KeyNTJOBXMMWNYJFB-UHFFFAOYSA-N
InChI
InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
IUPAC Name
4-amino-5-(ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide
SMILES
CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC
Pharmacology
IndicationInvestigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionAmisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
5-hydroxytryptamine receptor 7Proteinyes
antagonist
HumanP34969 details
5-hydroxytryptamine receptor 2AProteinunknown
antagonist
HumanP28223 details
Related Articles
AbsorptionBioavailability is 48% following oral administration.
Volume of distributionNot Available
Protein bindingLow (17%)
MetabolismNot Available
Route of eliminationNot Available
Half lifeApproximately 12 hours
ClearanceNot Available
ToxicityOverdoses of amisulpride have been linked with torsades de pointes.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Amisulpride is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineAmisulpride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineAmisulpride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineAmisulpride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAmisulpride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amisulpride.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Amisulpride.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amisulpride.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Amisulpride.Approved
adipiplonThe risk or severity of adverse effects can be increased when Amisulpride is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amisulpride.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Amisulpride.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Amisulpride.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amisulpride.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Amantadine.Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amisulpride.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Amisulpride.Experimental
AmphetamineAmisulpride may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amisulpride.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Amisulpride.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Amisulpride.Vet Approved
AzelastineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Amisulpride.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Amisulpride.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amisulpride.Approved
BenzphetamineAmisulpride may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Amisulpride is combined with Benzyl alcohol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Amisulpride.Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Amisulpride.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amisulpride.Approved, Illicit
BromocriptineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Amisulpride.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amisulpride.Approved, Investigational
BuprenorphineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Amisulpride.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amisulpride.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Amisulpride.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amisulpride.Approved, Illicit, Vet Approved
CabergolineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Cabergoline.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amisulpride.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Amisulpride.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Amisulpride.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amisulpride.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amisulpride.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amisulpride.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amisulpride.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorphenamine.Approved
ChlorphentermineAmisulpride may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amisulpride.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amisulpride.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amisulpride.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Amisulpride.Approved
ClemastineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Amisulpride is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amisulpride.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amisulpride.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amisulpride.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amisulpride.Approved, Illicit
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Amisulpride.Approved
CyclizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amisulpride.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amisulpride.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Amisulpride is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amisulpride.Approved
DesipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amisulpride.Approved
DetomidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amisulpride.Approved, Vet Approved
DextroamphetamineAmisulpride may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amisulpride.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amisulpride.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amisulpride.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amisulpride.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amisulpride.Approved, Illicit, Vet Approved
DiethylpropionAmisulpride may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amisulpride.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amisulpride.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amisulpride.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amisulpride.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amisulpride.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amisulpride.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Amisulpride is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Illicit
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Amisulpride.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amisulpride.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amisulpride.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amisulpride.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Amisulpride.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Amisulpride.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Amisulpride is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amisulpride.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amisulpride.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amisulpride.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amisulpride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Amisulpride.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Amisulpride.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amisulpride.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amisulpride.Approved
EthanolAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amisulpride.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amisulpride.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amisulpride.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amisulpride.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amisulpride.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amisulpride.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amisulpride.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amisulpride.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amisulpride.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amisulpride.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amisulpride.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amisulpride.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amisulpride.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amisulpride.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amisulpride.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amisulpride.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Amisulpride.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amisulpride.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Amisulpride is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amisulpride.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Amisulpride.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amisulpride.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amisulpride.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amisulpride.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Amisulpride.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amisulpride.Approved
HydrocodoneAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amisulpride.Approved, Illicit
Hydroxyamphetamine hydrobromideAmisulpride may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Amisulpride.Approved
ImipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Indalpine.Investigational, Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amisulpride.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amisulpride.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amisulpride.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amisulpride.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amisulpride.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amisulpride.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Amisulpride.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amisulpride.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amisulpride.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Amisulpride.Approved, Investigational
LisdexamfetamineAmisulpride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Amisulpride.Approved
LofentanilThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amisulpride.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Amisulpride.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amisulpride.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Amisulpride.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amisulpride.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amisulpride.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Amisulpride.Approved
MephedroneAmisulpride may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAmisulpride may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amisulpride.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amisulpride.Approved, Illicit
MequitazineAmisulpride may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amisulpride.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Amisulpride.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Amisulpride.Approved, Illicit
MethamphetamineAmisulpride may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amisulpride.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amisulpride.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amisulpride.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Amisulpride.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amisulpride.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amisulpride.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.Approved, Investigational
MetyrosineAmisulpride may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amisulpride.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Amisulpride.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
MirtazapineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAAmisulpride may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amisulpride.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Amisulpride.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amisulpride.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amisulpride.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Amisulpride.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amisulpride.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amisulpride.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amisulpride.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amisulpride.Approved
OpiumThe risk or severity of adverse effects can be increased when Amisulpride is combined with Opium.Approved, Illicit
OrphenadrineAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Amisulpride.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amisulpride.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amisulpride.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amisulpride.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amisulpride.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amisulpride.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amisulpride.Approved
ParaldehydeAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amisulpride.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amisulpride.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amisulpride.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Amisulpride.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Amisulpride.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amisulpride.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amisulpride.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amisulpride.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amisulpride.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenoxyethanol.Approved
PhentermineAmisulpride may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amisulpride.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amisulpride.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Amisulpride.Approved
PiribedilThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pomalidomide.Approved
PramipexoleThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Amisulpride.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amisulpride.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amisulpride.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Amisulpride is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amisulpride.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Amisulpride.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amisulpride.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Amisulpride.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amisulpride.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Amisulpride.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amisulpride.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Amisulpride.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Amisulpride is combined with PSD502.Investigational
PseudoephedrineAmisulpride may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Amisulpride.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amisulpride.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Amisulpride.Approved
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Amisulpride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amisulpride.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amisulpride.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amisulpride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amisulpride.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amisulpride.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Amisulpride.Investigational
RitobegronAmisulpride may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Amisulpride.Approved
RomifidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Romifidine.Vet Approved
RopiniroleThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amisulpride.Approved
RotigotineThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amisulpride.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amisulpride.Experimental
Sage 547The risk or severity of adverse effects can be increased when Amisulpride is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amisulpride.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Amisulpride.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Amisulpride.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amisulpride.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amisulpride.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
StiripentolThe risk or severity of adverse effects can be increased when Amisulpride is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amisulpride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Amisulpride.Approved, Investigational
SuvorexantAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Amisulpride.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amisulpride.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amisulpride.Approved
TetracaineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amisulpride.Investigational
ThalidomideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amisulpride.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amisulpride.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Amisulpride.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amisulpride.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amisulpride.Approved
TiagabineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Amisulpride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Amisulpride is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Amisulpride.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amisulpride.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Amisulpride.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amisulpride.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amisulpride.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amisulpride.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Amisulpride is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Amisulpride.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Amisulpride.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Amisulpride.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amisulpride.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amisulpride.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amisulpride.Approved, Investigational
ZolpidemAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amisulpride.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Amisulpride.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amisulpride.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceUS4401822
General References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
  2. Moller HJ: Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101-11. [PubMed:14642970 ]
  3. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800 ]
  4. Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002 Feb;159(2):180-90. [PubMed:11823257 ]
  5. Rehni AK, Singh TG, Chand P: Amisulpride-induced seizurogenic effect: a potential role of opioid receptor-linked transduction systems. Basic Clin Pharmacol Toxicol. 2011 May;108(5):310-7. doi: 10.1111/j.1742-7843.2010.00655.x. Epub 2010 Dec 22. [PubMed:21176108 ]
External Links
ATC CodesN05AL05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.864
Blood Brain Barrier+0.9441
Caco-2 permeable-0.7127
P-glycoprotein substrateSubstrate0.7242
P-glycoprotein inhibitor INon-inhibitor0.8209
P-glycoprotein inhibitor IINon-inhibitor0.8668
Renal organic cation transporterNon-inhibitor0.7899
CYP450 2C9 substrateNon-substrate0.794
CYP450 2D6 substrateNon-substrate0.8272
CYP450 3A4 substrateSubstrate0.5667
CYP450 1A2 substrateNon-inhibitor0.8888
CYP450 2C9 inhibitorNon-inhibitor0.8348
CYP450 2D6 inhibitorNon-inhibitor0.8572
CYP450 2C19 inhibitorNon-inhibitor0.8578
CYP450 3A4 inhibitorNon-inhibitor0.8942
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9081
Ames testNon AMES toxic0.5931
CarcinogenicityNon-carcinogens0.6637
BiodegradationNot ready biodegradable0.8868
Rat acute toxicity2.4706 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9398
hERG inhibition (predictor II)Inhibitor0.7128
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point181-182 °CPhysProp
logP1.06MANNHOLD,R ET AL. (1990)
pKa9.37Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.293 mg/mLALOGPS
logP1.5ALOGPS
logP0.25ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)7.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity99.84 m3·mol-1ChemAxon
Polarizability39.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids and derivatives. These are benzoic acids (or derivative thereof) containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids and derivatives
Alternative Parents
Substituents
  • Salicylamide
  • Aminobenzoic acid or derivatives
  • Methoxyaniline
  • Benzamide
  • Aminobenzamide
  • Methoxybenzene
  • Substituted aniline
  • Phenol ether
  • Benzoyl
  • Anisole
  • Aniline
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Primary aromatic amine
  • Sulfonyl
  • Sulfone
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
  2. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. [PubMed:16696579 ]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
  2. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. [PubMed:16696579 ]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL: Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009 Jul;205(1):119-28. doi: 10.1007/s00213-009-1521-8. Epub 2009 Apr 1. [PubMed:19337725 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Tyson PJ, Roberts KH, Mortimer AM: Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004 Jun;114(6):593-611. [PubMed:15204055 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:22 / Updated on August 17, 2016 12:24